STOCK TITAN
  1. Home
  2. News
  3. FOXO

FOXO Technologies Inc. - FOXO STOCK NEWS

Welcome to our dedicated page for FOXO Technologies news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO Technologies stock.

FOXO Technologies Inc. (symbol: FOXO) is leading the charge in transforming the global longevity and life insurance industries through cutting-edge epigenetic technology and AI-driven solutions. Founded under the names Yousurance and Life Epigenetics, the company has redefined how we understand and measure health and aging.

FOXO’s core business revolves around commercializing longevity science by utilizing epigenetic biomarkers to assess the biological age and health status of individuals. This revolutionary approach not only impacts life insurance underwriting protocols but also engages consumers directly through an advanced platform.

With a focus on DNA methylation, FOXO leverages supervised machine learning and artificial intelligence to pinpoint molecular signs of aging and health conditions. This enables more accurate risk assessment and personalized health insights, setting new standards in the insurance sector.

Recent achievements include groundbreaking advancements in epigenetic research and the integration of AI to enhance the precision of health evaluations. The company's current projects aim to further refine these technologies and expand their application range, ensuring they remain at the forefront of innovation in their field.

Financially, FOXO Technologies Inc. is committed to sustained growth and solidifying its market presence through strategic partnerships and continual investment in research and development. Their collaborations with leading scientific institutions and industry partners underscore their commitment to excellence and innovation.

Stay updated with the latest news and developments to see how FOXO Technologies Inc. continues to shape the future of longevity and health insurance.

News

FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global

Rhea-AI Summary
FOXO Technologies Inc. announces a proposed merger with M2i Global, Inc. to focus on securing the nation's supply of critical materials and resources. The merger aims to develop a global value supply chain for critical minerals for the U.S. government and free trade partners, as well as create a strategic mineral reserve in partnership with the U.S. Federal Government. The collaboration brings together extensive experience, knowledge, and resources to drive value for shareholders and enhance operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
acquisition
-
News

FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors

Rhea-AI Summary
FOXO Technologies Inc. appoints Francis Colt deWolf to its Board of Directors, bringing over 20 years of experience in the financial services sector. The Company also received a notice of noncompliance from NYSE Regulation regarding its audit committee composition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
management
-
News

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) has announced the formalization of its collaboration with KR8.ai Inc. and the exclusive license to KR8's AI-based software to support the development and commercial launch of its new health and wellness offering - the VITHAR™ AI Health Coach. The company aims to provide personalized health and wellness recommendations by leveraging epigenetic data, genetic insight, and growing patent estate with AI-driven analytic software and proprietary algorithms. The goal is to capture a meaningful share of the Health and Fitness App Market, which is projected to reach $35.7 billion by 2030, through a cost-effective go-to-market strategy. The new app will require users to send a saliva or blood sample, and the technology will combine this information with user health stats, as well as peer-reviewed clinical studies and other verified health resources to provide customized AI-driven health recommendations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.49%
Tags
AI
News

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

Rhea-AI Summary
FOXO Technologies Inc. (Ticker: FOXO) received a notice of noncompliance from NYSE Regulation due to the failure to timely file the Company’s Form 10-Q for the period ended September 30, 2023. The Company is committed to regaining compliance with the NYSE American’s continued listing requirements and has taken steps to enhance its financial infrastructure and ensure the highest standards of corporate governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
News

FOXO Technologies On Track to Commence Commercial Rollout of VITHAR™ AI Health Coach in Early 2024

Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) expects a reduction in losses of over $10 million for the third quarter of 2023 compared to the prior quarter. The company provided a business update on the planned commercial rollout of its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, and anticipates reporting financial results for the three and nine months ended September 30, 2023. The reduction in losses includes cash operational cost reductions in excess of $2.1 million over the second quarter of 2023. The company also plans to leverage social media influencers to enhance the commercial launch of the VITHAR AI Health Coach and expects annualized cost savings in excess of 52% for 2023, aiming to maintain a lean operating infrastructure to drive profitability following the commercial launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.82%
Tags
AI
-
News

FOXO Technologies Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q

Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. The Company has a six-month initial cure period to file the Form 10-Q with the SEC, with the possibility of an additional six-month cure period if needed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
News

FOXO Technologies Provides Reminder for Webinar to be Held Today, November 10th at 10 AM Eastern Time, to Unveil VITHAR™ AI Health Coach

Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) announces a webinar to unveil its new direct-to-consumer app, the VITHAR™ AI Health Coach, designed to combine health and epigenetic data for actionable insights and coaching.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
AI
-
News

FOXO Technologies to Unveil VITHAR™ AI Health Coach; Schedules Webinar for Friday, November 10th at 10 AM Eastern Time

Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) announced a webinar on November 10, 2023, to introduce its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which will leverage epigenetic data and algorithms to provide personalized health insights and coaching. The app aims to improve user's overall health and longevity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.87%
Tags
AI
-
News

FOXO Technologies Expects Class A Common Stock to Resume Trading, Today, November 7, in Connection with 1-for-10 Reverse Stock Split

Rhea-AI Summary
FOXO Technologies Inc. (NYSE American: FOXO) is set to resume trading after a 1-for-10 reverse stock split to comply with NYSE American Company Guide. The company plans to drive commercialization through a new direct-to-consumer offering in partnership with KR8.ai.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.24%
Tags
none
News

FOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Company’s Epigenetic Data with the Power of AI

Rhea-AI Summary
FOXO Technologies Inc. plans to launch a new subscription-based, direct-to-consumer product offering that provides personalized health and wellness recommendations. The offering will combine FOXO's machine learning models, epigenetic biomarkers, and clinical data. The company has formed a collaboration with KR8.ai Inc. and secured an exclusive license to KR8's AI-based software to support the development and launch of the new offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.72%
Tags
AI

FAQ

What is the current stock price of FOXO Technologies (FOXO)?

The current stock price of FOXO Technologies (FOXO) is $0.5383 as of November 22, 2024.

What is the market cap of FOXO Technologies (FOXO)?

The market cap of FOXO Technologies (FOXO) is approximately 9.4M.

What does FOXO Technologies Inc. specialize in?

FOXO Technologies Inc. specializes in applying epigenetic technology and AI to transform the life insurance industry through advanced risk assessment and consumer engagement.

How does FOXO's technology work?

FOXO uses DNA methylation and AI to identify molecular biomarkers that reveal insights into an individual's health and aging, allowing for more accurate underwriting in life insurance.

What are epigenetic biomarkers?

Epigenetic biomarkers are molecular signs found in DNA that indicate current health status and biological age, which FOXO utilizes to enhance life insurance underwriting.

How is FOXO Technologies Inc. impacting the life insurance industry?

By employing epigenetic technology and AI, FOXO is revolutionizing life insurance underwriting, making it more precise and personalized.

What are some recent achievements of FOXO Technologies Inc.?

Recent milestones include advancements in epigenetic research, development of AI-driven health assessments, and strategic partnerships to enhance their technology platform.

What is FOXO Technologies Inc.’s approach to consumer engagement?

FOXO engages consumers through a platform that provides personalized health insights based on epigenetic biomarkers, enhancing their understanding of personal health and longevity.

Who are FOXO Technologies Inc.'s partners?

FOXO collaborates with leading scientific institutions and industry partners to advance their research and technology applications in the life insurance sector.

What is DNA methylation?

DNA methylation is a biological process where methyl groups are added to DNA, affecting gene expression without altering the DNA sequence. FOXO uses this process to identify health biomarkers.

Where is FOXO Technologies Inc. headquartered?

FOXO Technologies Inc. is headquartered in Minneapolis, as indicated in their latest news release.

What is the future outlook for FOXO Technologies Inc.?

FOXO is focused on continued innovation in epigenetic technology and AI, aiming for sustained growth and expanded applications in the life insurance industry.

Stock FOXO logo
FOXO Technologies Inc.

NYSE:FOXO

FOXO Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

FOXO Stock Data

9.43M
15.38M
12%
2.26%
0.39%
Health Information Services
Services-commercial Physical & Biological Research
Link
United States of America
MINNEAPOLIS